[53] IAPAM
Four HRT treatment pathways are available through Gala GLP-1: Estradiol pill or patch - designed to support relief from hot flashes, sleep disruption, and mood symptoms linked to the decline of estradiol through perimenopause and menopause Progesterone - designed to support uterine lining protection, sleep quality, and anxiety symptoms in eligible patients Vaginal estradiol - designed to support relief from vaginal dryness, discomfort during intercourse, and recurrent UTIs associated with local estrogen decline Non-hormonal options - available for patients for whom hormonal treatment is not clinically appropriate, designed to support relief from hot flashes and night sweats through alternative mechanisms HRT safety considerations: Hormone therapy products - both FDA-approved and pharmacy-compounded - carry documented risks including blood clots, stroke, breast cancer, and endometrial cancer (in patients with an intact uterus receiving estrogen without adequate progesterone)
Rather than describing outcomes in terms of symptom relief or treatment, investigators focus on mechanistic language such as changes in specific markers, pathways, or structural features
69,70 Notably, findings from pharmacovigilance databases and real-world cohorts have been inconsistent, with some reports suggesting an association with specific agents, such as semaglutide, while others have not observed such relationships
